FDA and Its Role in Drug Development

Area of Science:

• Oncology
• Drug Development
• Regulatory Affairs

Background:

• The Food and Drug Administration (FDA) Oncology Center of Excellence plays a crucial role in advancing cancer treatments.
• The landscape of oncology drug development is constantly evolving.
• The COVID-19 pandemic has significantly impacted healthcare and clinical research.

Purpose of the Study:

• To provide insights into recent modifications in oncology drug development.
• To clarify the current FDA drug approval process.
• To examine the evolving role of advanced practitioners in clinical trials.
• To discuss the impact of the COVID-19 pandemic on oncology research and practice.

Main Methods:

• Presentation by Dr. Richard Pazdur, Director of the FDA Oncology Center of Excellence, at JADPRO Live 2020.
• Discussion of regulatory changes and clinical trial execution.
• Analysis of pandemic-related adaptations in oncology.

Main Results:

• Key updates on oncology drug development and FDA approval processes were shared.
• The integral role of advanced practitioners in clinical trial execution was highlighted.
• Significant changes and adaptations driven by the COVID-19 pandemic were detailed.

Conclusions:

• The FDA remains committed to optimizing oncology drug development and approval.
• Advanced practitioners are essential for efficient clinical trial conduct.
• The oncology field has demonstrated resilience and adaptability in response to the pandemic.